A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
Authors:
Open Access
- 16 July 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 11, 608
Abstract
Background: The diagnostic use of biomarkers in body fluids of multiple sclerosis (MS) patients allows the monitoring of different pathophysiological aspects of the disease. We previously reported elevated cerebrospinal fluid (CSF) and serum levels of glial fibrillary acidic protein (GFAP) but not neurofilament light chain (NfL) in progressive (PMS) compared to relapsing–remitting MS (RRMS) patients. Objectives: We analyzed the glial marker chitinase-3-like protein 1 (CHI3L1) in the CSF and serum of PMS and RRMS patients. To capture the extent of glial processes in relation to axonal damage in each individual patient, we established a score based on CHI3L1, GFAP, and NfL and compared this score between RRMS and PMS patients and its association with the extended disability status scale (EDSS). Methods: For this retrospective study, we included 86 MS patients (47 RRMS and 39 PMS) and 20 patients with other non-inflammatory neurological diseases (OND) as controls. NfL and GFAP levels were determined by the single-molecule array (Simoa). CHI3L1 levels were measured with classical enzyme-linked immunosorbent assay. A score was calculated based on glial to axonal markers (CHI3L1*GFAP/NfL, referred to as “Glia score”). Results: CHI3L1 showed higher CSF levels in PMS vs. RRMS and controls (p < 0.001 and p < 0.0001, respectively), RMS vs. controls (p < 0.01), and higher serum levels for PMS vs. RRMS (p < 0.05). The Glia score was higher in the CSF of PMS compared to RRMS patients (p < 0.0001) and in the serum of PMS patients compared to RRMS (p < 0.01). Furthermore, the Glia score and CHI3L1 in serum but not in CSF correlated with the disability as determined by EDSS in the PMS group but not in the RRMS group (Spearman ρ = 0.46 and 0.45, p = 0.003 and 0.004, respectively). Discussion: Our data indicate the involvement of glial mechanisms during the pathogenesis of PMS. Moreover, a calculated score may help to differentiate between PMS and RMS in the CSF and monitor disease progression in the serum of PMS patients.Keywords
This publication has 44 references indexed in Scilit:
- Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis studyNeuropsychiatric Disease and Treatment, 2018
- Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosisEuropean Journal of Neurology, 2017
- The Role of Astrocytes in Multiple Sclerosis ProgressionFrontiers in Neurology, 2015
- Pathological mechanisms in progressive multiple sclerosisThe Lancet Neurology, 2015
- The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-upJournal of Neurology, Neurosurgery & Psychiatry, 2015
- Multiple sclerosis: Lessons from molecular neuropathologyExperimental Neurology, 2014
- Mechanisms of white matter damage in multiple sclerosisGlia, 2014
- Progressive multiple sclerosis: pathology and pathogenesisNature Reviews Neurology, 2012
- Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over timeBrain, 2002
- Multiple sclerosisThe Lancet, 2002